All In Biotech

Drug Trial Radar · NCT06150040

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

A Phase I/II Study to Evaluate the Safety Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Standard AZACITIDINE+ VENETOCLAX in Patients With Refractory Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Sep 11, 2024

Primary completion

Feb 18, 2025

Study completion Feb 18, 2025

Sponsor

Lead sponsor
Centre Leon BerardAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NETRIS Pharma
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.

Conditions

  • Acute Myeloid Leukemia Refractory

Interventions

  • NP137Drug

    IV infusion, 14mg/kg or 9mg/kg, every 2 weeks

  • Azacitidine InjectionDrug

    Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)

  • VenetoclaxDrug

    Orally, 70 mg, every day on Days 1-28

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety run in part : Incidence of Dose Limiting Toxicities (DLT)Time frame: 4 weeks
  2. Phase II part : Objective Response Rate (ORR)Time frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Léon Bérard

    Lyon, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.